Complete financial analysis of Aeterna Zentaris Inc. (AEZS.TO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aeterna Zentaris Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Medivir AB (publ) (MVIR-B.ST) Income Statement Analysis – Financial Results
- Recruiter.com Group, Inc. (RCRT) Income Statement Analysis – Financial Results
- L’Air Liquide S.A. (AI.PA) Income Statement Analysis – Financial Results
- Reunion Gold Corporation (RGDFF) Income Statement Analysis – Financial Results
- CF Acquisition Corp. V (CFFVW) Income Statement Analysis – Financial Results
Aeterna Zentaris Inc. (AEZS.TO)
About Aeterna Zentaris Inc.
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.50M | 5.64M | 5.26M | 3.65M | 532.00K | 26.88M | 923.00K | 911.00K | 545.00K | 11.00K | 6.18M | 33.67M | 36.05M | 27.70M | 63.24M | 38.48M | 42.07M | 41.39M | 247.39M | 194.03M | 128.33M | 64.28M | 27.50M | 5.61M | 4.25M | 2.79M | 4.47M | 2.04M |
| Cost of Revenue | 222.00K | 157.00K | 90.00K | 2.32M | 410.00K | 2.10M | 0.00 | 0.00 | 0.00 | 0.00 | 51.00K | 26.82M | 27.56M | 18.70M | 16.50M | 19.28M | 12.93M | 11.75M | 156.37M | 111.91M | 75.61M | 49.19M | 18.81M | 749.33K | 705.76K | 1.49M | 1.96M | 1.75M |
| Gross Profit | 4.28M | 5.48M | 5.17M | 1.34M | 122.00K | 24.78M | 923.00K | 911.00K | 545.00K | 11.00K | 6.12M | 6.85M | 8.49M | 9.00M | 46.74M | 19.20M | 29.14M | 29.65M | 91.02M | 82.11M | 52.72M | 15.09M | 8.69M | 4.86M | 3.55M | 1.30M | 2.52M | 291.89K |
| Gross Profit Ratio | 95.06% | 97.22% | 98.29% | 36.56% | 22.93% | 92.17% | 100.00% | 100.00% | 100.00% | 100.00% | 99.17% | 20.33% | 23.56% | 32.50% | 73.91% | 49.90% | 69.26% | 71.62% | 36.79% | 42.32% | 41.08% | 23.48% | 31.58% | 86.63% | 83.40% | 46.51% | 56.25% | 14.29% |
| Research & Development | 13.56M | 12.51M | 6.57M | 1.51M | 1.84M | 2.93M | 10.70M | 16.50M | 17.23M | 23.72M | 21.28M | 20.60M | 24.52M | 19.86M | 44.22M | 57.11M | 37.19M | 27.09M | 26.97M | 25.26M | 34.03M | 15.33M | 14.59M | 10.62M | 8.40M | 6.04M | 4.26M | 3.28M |
| General & Administrative | 8.72M | 8.23M | 5.92M | 4.76M | 6.62M | 8.89M | 8.20M | 7.15M | 11.31M | 9.84M | 8.97M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.08M | 1.72M | 1.42M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 40.48K | 8.23M | 1.35M | 1.13M | 1.21M | 3.11M | 5.10M | 6.75M | 6.89M | 13.69M | 12.32M | 13.25M | 0.00 | 11.88M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.72M | 8.23M | 7.27M | 5.89M | 7.83M | 12.00M | 13.29M | 13.89M | 18.20M | 13.69M | 12.32M | 13.25M | 16.17M | 11.88M | 16.04M | 17.33M | 20.40M | 17.24M | 42.04M | 35.10M | 22.44M | 11.29M | 4.08M | 1.72M | 1.42M | 0.00 | 0.00 | 0.00 |
| Other Expenses | -13.00K | -3.00K | -21.00K | -93.71K | 0.00 | -1.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.81M | 10.84M | 7.15M | 6.30M | 9.43M | 26.61M | 7.47M | 7.26M | 1.54M | 1.16M | 969.37K | 709.21K | -714.89K | -698.81K | -1.02M |
| Operating Expenses | 22.28M | 20.74M | 13.84M | 7.40M | 9.67M | 14.94M | 24.00M | 30.39M | 35.43M | 37.41M | 33.60M | 33.85M | 40.69M | 34.23M | 70.69M | 81.58M | 63.89M | 53.75M | 95.61M | 67.83M | 63.73M | 28.16M | 19.84M | 13.30M | 10.53M | 5.33M | 3.56M | 2.26M |
| Cost & Expenses | 22.51M | 20.89M | 13.93M | 9.72M | 10.08M | 17.04M | 24.00M | 30.39M | 35.43M | 37.41M | 33.65M | 60.67M | 68.25M | 52.93M | 87.20M | 100.86M | 76.82M | 65.50M | 251.98M | 179.75M | 139.34M | 77.35M | 38.65M | 14.05M | 11.24M | 6.82M | 5.52M | 4.01M |
| Interest Income | 1.13M | 4.00K | 7.00K | 4.00K | 593.00K | 278.00K | 75.00K | 150.00K | 143.00K | 168.00K | 185.00K | 6.97M | 6.24M | 207.00K | 349.00K | 0.00 | 0.00 | 1.45M | 1.60M | 0.00 | 1.65M | 0.00 | 0.00 | 2.41M | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 128.13K | 3.00K | 21.00K | 736.00K | 593.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.51M | 382.00K | 8.00K | 26.00K | 5.00K | 0.00 | 0.00 | 1.45M | 9.79M | 0.00 | 3.73M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.95M | 1.91M | 1.88M | 1.84M | 315.00K | 58.00K | 94.00K | 280.00K | 341.00K | 878.00K | 949.00K | 1.32M | 2.88M | 2.50M | 10.84M | 1.67M | 5.57M | 9.43M | 7.60M | 7.47M | 7.27M | 1.54M | 1.16M | 969.37K | 709.21K | 324.95K | 139.76K | 145.94K |
| EBITDA | -18.18M | -7.65M | -8.53M | 3.04M | -9.23M | 8.98M | -25.70M | -33.56M | -34.54M | -36.52M | -26.53M | -18.71M | -23.08M | -22.52M | -12.77M | -58.22M | -27.39M | -15.39M | -15.73M | 23.04M | -2.49M | -11.80M | -16.41M | -15.10M | -9.66M | -5.20M | -2.17M | -3.94M |
| EBITDA Ratio | -404.22% | -135.59% | -162.09% | -216.57% | -1,734.77% | 33.41% | -2,784.83% | -3,684.19% | -6,338.17% | -331,972.73% | -429.59% | -55.58% | -64.01% | -81.31% | -20.19% | -151.31% | -65.11% | -37.17% | -6.36% | 11.88% | -1.94% | -18.35% | -59.68% | -269.40% | -227.32% | -186.05% | -48.44% | -192.86% |
| Operating Income | -18.01M | -15.25M | -8.67M | -6.06M | -9.54M | 9.84M | -23.07M | -29.48M | -34.88M | -37.40M | -27.48M | -27.00M | -32.19M | -25.23M | -23.96M | -62.38M | -34.75M | -24.11M | 14.41M | 14.28M | -11.01M | -13.06M | -11.15M | -8.45M | -6.98M | -4.03M | -1.05M | -1.97M |
| Operating Income Ratio | -400.36% | -270.44% | -164.85% | -166.05% | -1,793.98% | 36.61% | -2,499.89% | -3,235.57% | -6,400.73% | -339,954.55% | -444.96% | -80.21% | -89.30% | -91.07% | -37.89% | -162.13% | -82.61% | -58.24% | 5.83% | 7.36% | -8.58% | -20.32% | -40.56% | -150.71% | -164.25% | -144.19% | -23.44% | -96.43% |
| Total Other Income/Expenses | 1.46M | -7.47M | 11.26M | 1.34M | 3.48M | -203.00K | 2.80M | 4.52M | -15.34M | 20.32M | 236.00K | 3.86M | 6.23M | 2.01M | -766.00K | 3.74M | 756.00K | 2.28M | -8.45M | -6.43M | -3.29M | 1.51M | 1.83M | 7.62M | 3.39M | 1.49M | 1.26M | 2.12M |
| Income Before Tax | -16.55M | -22.73M | -8.48M | -4.72M | -6.23M | 9.64M | -20.28M | -24.96M | -50.23M | -17.08M | -27.24M | -20.41M | -25.96M | -23.22M | -24.72M | -58.64M | -34.00M | -21.83M | 5.97M | 7.85M | -14.30M | -11.55M | -9.32M | -825.24K | -3.59M | -2.53M | 209.64K | 145.94K |
| Income Before Tax Ratio | -367.99% | -402.96% | -161.16% | -129.33% | -1,171.05% | 35.86% | -2,196.64% | -2,739.74% | -9,216.15% | -155,236.36% | -441.13% | -60.63% | -72.01% | -83.81% | -39.10% | -152.40% | -80.82% | -52.74% | 2.41% | 4.05% | -11.14% | -17.97% | -33.91% | -14.72% | -84.51% | -90.70% | 4.69% | 7.14% |
| Income Tax Expense | -1.47M | 7.47M | -109.00K | 395.00K | -188.00K | 5.45M | -3.48M | -4.52M | -85.00K | 111.00K | -34.06M | 6.97M | 1.10M | 26.00K | 5.00K | 1.18M | -1.96M | -29.13M | 7.33M | 6.89M | 4.57M | 2.81M | -2.98M | -9.11M | -4.26M | -1.49M | -1.12M | 72.97K |
| Net Income | -16.55M | -30.20M | -8.37M | -5.12M | -6.04M | 4.19M | -16.80M | -24.96M | -50.14M | -16.56M | 6.82M | -20.41M | -27.07M | -23.22M | -24.72M | -59.82M | -32.30M | 33.39M | 10.57M | -4.79M | -21.71M | -16.38M | -2.18M | 662.10K | -2.72M | -2.53M | 69.88K | 72.97K |
| Net Income Ratio | -367.99% | -535.43% | -159.09% | -140.14% | -1,135.71% | 15.58% | -1,819.72% | -2,739.74% | -9,200.55% | -150,581.82% | 110.36% | -60.63% | -75.08% | -83.81% | -39.10% | -155.46% | -76.77% | 80.67% | 4.27% | -2.47% | -16.91% | -25.48% | -7.92% | 11.81% | -63.98% | -90.70% | 1.56% | 3.57% |
| EPS | -3.41 | -6.22 | -1.82 | -3.11 | -8.75 | 6.37 | -28.07 | -60.29 | -453.60 | -701.63 | 600.00 | -2.58K | -4.30K | -4.60K | -6.52K | -16.87K | -9.11K | 9.60K | 3.45K | -1.58K | -7.57K | -6.37K | -1.06K | -3.30K | -1.59K | -1.56K | 0.10 | 0.10 |
| EPS Diluted | -3.41 | -6.22 | -1.82 | -3.11 | -8.63 | 6.14 | -28.07 | -58.51 | -366.08 | -701.60 | 600.00 | -2.58K | -4.30K | -4.60K | -6.52K | -16.87K | -9.11K | 9.30K | 3.45K | -1.56K | -7.57K | -6.37K | -1.03K | -3.30K | -1.59K | -1.36K | 0.10 | 0.10 |
| Weighted Avg Shares Out | 4.86M | 4.86M | 4.60M | 1.64M | 690.51K | 657.63K | 598.35K | 413.96K | 110.54K | 23.61K | 11.79K | 7.91K | 6.30K | 5.04K | 3.79K | 3.55K | 3.55K | 3.47K | 3.08K | 3.04K | 2.87K | 2.57K | 2.06K | 1.97K | 1.71K | 1.63K | 699.78K | 699.78K |
| Weighted Avg Shares Out (Dil) | 4.86M | 4.86M | 4.60M | 1.64M | 699.78K | 681.39K | 598.35K | 426.61K | 136.97K | 23.61K | 11.79K | 7.92K | 6.30K | 5.04K | 3.79K | 3.55K | 3.55K | 3.50K | 3.08K | 3.07K | 2.87K | 2.57K | 2.11K | 1.97K | 1.71K | 1.86K | 699.78K | 699.78K |
Source: https://incomestatements.info
Category: Stock Reports